EX-10.10



 Exhibit 10.10 
 SECURITIES PURCHASE AGREEMENT 
 THIS
SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 26, 2013, by and among Lipocine Inc., a Delaware corporation (the “Company”)
(f.k.a. Marathon Bar Corp.), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). 

RECITALS 
 A. The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the
“Commission”) under the Securities Act. 
 B. Each Purchaser, severally and not jointly, wishes
to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, that aggregate number of shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company,
determined as set forth in Section 2.1(a) below (which aggregate amount for all Purchasers together shall be collectively referred to herein as the “Shares”). 

C. The Shares are referred to herein as the “Securities”. 

D. The Company has engaged Ladenburg Thalmann & Co. as its exclusive placement agent (the “Placement
Agent”) for the offering of the Shares on a “best efforts” basis. 
 E. Contemporaneously with the
execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement, substantially in the form attached hereto as Exhibit A (the “Registration Rights
Agreement”), pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to the Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable
state securities laws. 
 NOW, THEREFORE, in consideration of the mutual covenants
contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this Section 1.1:

 “Action” means any action, suit, inquiry, notice of violation, proceeding (including any partial
proceeding such as a deposition) or investigation pending or, to the Company’s Knowledge, threatened in writing (or otherwise) against the Company or any of their respective properties or any officer, director or employee of the Company acting
in his or her capacity as an officer, director or employee before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency, regulatory authority, stock market, stock exchange or trading facility.


  
 1. 









 “Affiliate” means, with respect to any Person, any other Person
that, directly or indirectly through one or more intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 144. With respect to a Purchaser, any investment fund or
managed account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 
 “Agreement” shall have the meaning ascribed to such term in the Preamble. 
 “Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 

“Closing” means the closing of the purchase by the Purchasers listed on Annex A hereto and sale by the
Company of Shares to such Purchasers pursuant to this Agreement on the Closing Date as provided in Section 2.1(a) hereof. 
 “Closing Date” means the third (3rd) Trading Day after the date on which this Agreement has been executed and delivered by all parties hereto, unless on such date the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 (other
than those to be satisfied at the Closing) shall not have been satisfied or waived, in which case the Closing Date shall be on the third (3rd) Trading Day after the date on which the last to be satisfied or waived of the conditions set forth in
Sections 2.1, 2.2, 5.1 and 5.2 (other than those to be satisfied at the Closing) shall have been satisfied or waived. 

“Common Stock” has the meaning set forth in the Recitals, and also includes any securities into which the Common
Stock may hereafter be reclassified or changed. 
 “Company Counsel” means Cooley LLP.

 “Company Deliverables” has the meaning set forth in Section 2.2(a). 

“Company’s Knowledge” means with respect to any statement made to the knowledge of the Company, that the
statement is based upon the actual knowledge of the officers of the Company having responsibility for the matter or matters that are the subject of the statement. 
 “Control” (including the terms “controlling”, “controlled” by or “under common control with”) means the possession, direct
or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Disclosure Materials” has the meaning set forth in Section 3.1(h). 

“Effective Date” means the date on which the initial Registration Statement required by Section 2(a) of the
Registration Rights Agreement is first declared effective by the Commission. 
 “Environmental Laws” has
the meaning set forth in Section 3.1(l). 
 “Exchange Act” means the Securities Exchange Act of
1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder. 

“GAAP” means U.S. generally accepted accounting principles, as applied by the Company. 

“Intellectual Property” has the meaning set forth in Section 3.1(r). 

  
 2. 









 “Irrevocable Transfer Agent Instructions” means, with respect to the
Company, the Irrevocable Transfer Agent Instructions, in the form of Exhibit D, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent. 

“Lien” means any lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or
other restrictions of any kind. 
 “Material Adverse Effect” means a material adverse effect on the
results of operations, assets, business or financial condition of the Company, except that any of the following, either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by changes or circumstances
affecting general market conditions in the U.S. economy or which are generally applicable to the industry in which the Company operates provided that such effects are not borne disproportionately by the Company, (ii) effects resulting from or
relating to the announcement or disclosure of the sale of the Securities or other transactions contemplated by this Agreement, or (iii) effects caused by any event, occurrence or condition resulting from or relating to the taking of any action
in accordance with this Agreement. 
 “Material Contract” means any contract of the Company that has
been filed or was required to have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K (including, for purposes hereof, any contracts that are required to be filed as an exhibit
to a Form 10). 
 “Material Permits” has the meaning set forth in Section 3.1(p). 

“New York Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan.

 “Outside Date” means August 2, 2013. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on or quoted
for trading, which, as of the date of this Agreement and the Closing Date, shall be the OTC Bulletin Board. 

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an
investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
 “Purchase
Price” means $6.00 per share of Common Stock. 
 “Purchaser Deliverables” has the meaning
set forth in Section 2.2(b). 
 “Registration Rights Agreement” has the meaning set forth in the
Recitals. 
 “Registration Statement” means a registration statement meeting the requirements set forth
in the Registration Rights Agreement and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement). 

  
 3. 









 “Required Approvals” has the meaning set forth in
Section 3.1(e). 
 “Reverse Merger Transaction” means the transaction whereby the Company (f.k.a.
Marathon Bar Corp.) issued a certain number of shares of Common Stock in exchange for 100% of the ownership interest of Lipocine Operating Inc. Upon completion of the Reverse Merger Transaction, Lipocine Operating Inc. became a direct wholly-owned
subsidiary of the Company. 
 “Rule 144” means Rule 144 promulgated by the Commission pursuant
to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Reports” has the meaning set forth in Section 3.1(h). 

“Secretary’s Certificate” has the meaning set forth in Section 2.2(a)(vi). 

“Securities Act” means the Securities Act of 1933, as amended. 

“Short Sales” include, without limitation, (i) all “short sales” as defined in Rule 200
promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions”
(as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. 

“Subscription Amount” means with respect to each Purchaser, the aggregate amount to be paid for the Shares
purchased hereunder as indicated on such Purchaser’s signature page to this Agreement next to the heading “Aggregate Purchase Price (Subscription Amount)”. 
 “Subsidiary” means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest. 

“Trading Affiliate” has the meaning set forth in Section 3.2(h). 

“Trading Day” means (i) a day on which the Common Stock is listed or quoted and traded on its Principal
Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the
OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by Pink Sheets LLC (or any similar
organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business
Day. 
 “Trading Market” means whichever of the New York Stock Exchange, the NYSE-Mkt, the Nasdaq Global
Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 
 “Transaction Documents” means this Agreement, the exhibits attached hereto, the Registration Rights Agreement, the Irrevocable Transfer Agent Instructions and any other documents
or agreements executed in connection with the transactions contemplated hereunder. 

  
 4. 









 “Transfer Agent” means Globex Transfer, LLC, or any successor
transfer agent for the Company. 
 ARTICLE 2 
 PURCHASE AND SALE 
 2.1 Closing. 

(a) Amount. Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to
each Purchaser listed on Annex A hereto, and each Purchaser listed on Annex A hereto shall, severally and not jointly, purchase from the Company, such number of Shares of Common Stock equal to the quotient resulting from dividing
(i) the aggregate purchase price for such Purchaser, as indicated below such Purchaser’s name on the signature page of this Agreement (the “Subscription Amount”) by (ii) the Purchase Price, rounded down to the
nearest whole Share. 
 (b) Closing. The Closing of the purchase and sale of the Shares shall take place at the offices
of Company Counsel, 3175 Hanover Street, Palo Alto, California on the Closing Date or at such other locations or remotely by facsimile transmission or other electronic means as the parties may mutually agree. 

(c) Form of Payment. On the Closing Date, (i) each Purchaser listed on Annex A hereto shall wire its Subscription
Amount, in United States dollars and in immediately available funds, in the amount set forth as the “Aggregate Purchase Price (Subscription Amount)” indicated below such Purchaser’s name on the applicable signature page hereto by wire
transfer to the Company’s account, as set forth in instructions previously provided to the Purchasers, and (ii) the Company shall irrevocably instruct the Transfer Agent to deliver to each Purchaser listed on Annex A hereto one or
more stock certificates, free and clear of all restrictive and other legends except as expressly provided in Section 4.1(b) hereof, evidencing the number of Shares such Purchaser is purchasing as is calculated in accordance with
Section 2.1(a) above, within three (3) Business Days after the Closing. 
 2.2 Closing Deliveries. 

 (a) On or prior to the Closing with respect to the Purchasers listed on Annex A hereto, the Company shall
issue, deliver or cause to be delivered to such Purchaser the following (the “Company Deliverables”): 

(i) this Agreement, duly executed by the Company; 
 (ii) facsimile copies of one or more stock certificates, free and clear of all restrictive and other legends except as provided in Section 4.1(b) hereof, evidencing the Shares subscribed for
by such Purchaser hereunder, registered in the name of such Purchaser as set forth on the Stock Certificate Questionnaire included as Exhibit B-2 hereto (the “Stock Certificates”), with the original Stock
Certificates delivered within three (3) Business Days of Closing; 
 (iii) a legal opinion of Company Counsel dated
as of the Closing Date in the form attached hereto as Exhibits C executed by such counsel and addressed to such Purchasers; 
 (iv) the Registration Rights Agreement, duly executed by the Company; 

  
 5. 









 (v) duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by
the Transfer Agent; 
 (vi) a certificate of the Secretary of the Company (the “Secretary’s
Certificate”), dated as of the Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving the transactions contemplated by this Agreement and the
other Transaction Documents and the issuance of the Securities, (b) certifying the current versions of the certificate of incorporation, as amended, and by-laws of the Company and (c) certifying as to the signatures and authority of
persons signing the Transaction Documents and related documents on behalf of the Company, in the form attached hereto as Exhibit E; 
 (vii) the Compliance Certificate referred to in Section 5.1(g); 

(viii) a certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State of
Delaware, as of a date within five (5) days of the Closing Date; 
 (ix) a certificate evidencing the
Company’s qualification as a foreign corporation and good standing issued by the Secretary of State of the State of Utah, as of a date within ten (10) days of the Closing Date; and 

(x) a certified copy of the Certificate of Incorporation, as certified by the Secretary of State of the State of Delaware, as of
a date within ten (10) days of the Closing Date. 
 (b) On or prior to the Closing with respect to the Purchasers
listed on Annex A hereto, each Purchaser shall deliver or cause to be delivered to the Company the following (the “Purchaser Deliverables”): 
 (i) this Agreement, duly executed by such Purchaser; 
 (ii) its
Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth as the “Aggregate Purchase Price (Subscription Amount)” indicated below such Purchaser’s name on the applicable signature page
hereto by wire transfer to the Company’s account as previously provided to the Purchasers; 
 (iii) a fully
completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex B to the Registration Rights Agreement; and 
 (iv) a fully completed and duly executed Accredited Investor Questionnaire and Stock Certificate Questionnaire in the forms attached hereto as Exhibits B-1 and B-2, respectively.


  
 6. 









 ARTICLE 3 
 REPRESENTATIONS AND WARRANTIES 
 3.1 Representations and Warranties of
the Company. The Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date), to each of the Purchasers
that, except as disclosed in the SEC Reports: 
 (a) Subsidiaries. The Company has no direct or indirect Subsidiaries
other than Lipocine Operating Inc., a Delaware corporation. 
 (b) Organization and Qualification. The Company is an
entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the State of Delaware, with the requisite corporate power and authority to own or lease and use its properties and assets and to carry on its
business as currently conducted. The Company is not in violation of any of the provisions of its certificate of incorporation or bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have a Material
Adverse Effect. 
 (c) Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority
to enter into and to consummate the transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction
Documents to which it is a party by the Company and the consummation by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares) have been duly authorized by all necessary corporate
action on the part of the Company, and no further corporate action is required by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with the Required Approvals. Each of the Transaction Documents
to which it is a party has been (or upon delivery will have been) duly executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute the legal, valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of,
creditors’ rights and remedies or by other equitable principles of general application. There are no shareholder agreements, voting agreements, or other similar arrangements with respect to the Company’s capital stock to which the Company
is a party or, to the Company’s Knowledge, between or among any of the Company’s stockholders. 
 (d) No
Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the
issuance of the Shares) do not and will not (i) conflict with or violate any provisions of the Company’s certificate of incorporation or bylaws or otherwise result in a violation of the organizational documents of the Company,
(ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or give to others any
rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company is subject or decree (including federal and state securities laws and regulations and the rules and regulations, assuming the correctness of the representations and warranties
made by the Purchasers herein, of any self regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company is bound or affected), except in the
case of clause (iii) such as would not, individually or in the aggregate, have a Material Adverse Effect. 
 (e)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the 

  
 7. 









 
execution, delivery and performance by the Company of the Transaction Documents (including the issuance of the Securities), other than (i) the filing with the Commission of one or more
Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities on Form D with the
Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for the issuance and sale of the Common Stock and the listing of the Common Stock for
trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with Section 4.9 of this Agreement and (vi) those that have been made or obtained prior to the date of
this Agreement (collectively, the “Required Approvals”). 
 (f) Issuance of the Securities. The
Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions on
transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights. Assuming the accuracy of the representations and warranties of the Purchasers in this Agreement,
the Shares will be issued in compliance with all applicable federal and state securities laws. 
 (g) Capitalization. The
number of shares and type of all authorized, issued and outstanding capital stock, options and other securities of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company) has
been set forth in the SEC Reports and has changed since the date set forth in such SEC Reports only to reflect stock option exercises and grants and warrant exercises that have not, individually or in the aggregate, had a material affect on the
issued and outstanding capital stock, options and other securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and non-assessable, have been issued in compliance in all material
respects with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase any capital stock of the Company. Except as set forth
in the SEC Reports: (i) no shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) there are no outstanding options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares of capital stock of the Company, or contracts,
commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of capital stock of the Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares of capital stock of the Company; (iii) there are no outstanding debt securities, notes, credit agreements, credit facilities or other
agreements, documents or instruments evidencing indebtedness of the Company or by which the Company is or may become bound; (iv) there are no financing statements securing obligations in any material amounts, either singly or in the aggregate,
filed in connection with the Company; (v) there are no agreements or arrangements under which the Company is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement);
(vi) there are no outstanding securities or instruments of the Company or which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company is or may become bound to
redeem a security of the Company; (vii) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (viii) the Company does not have any stock appreciation
rights or “phantom stock” plans or agreements or any similar plan or agreement; and (ix) the Company has no liabilities or obligations required to be disclosed in the SEC Reports (including, for purposes hereof, any liabilities that
are 

  
 8. 









 
required to be disclosed in a Form 10) but not so disclosed in the SEC Reports, other than those incurred in the ordinary course of the Company’s businesses and which, individually or in the
aggregate, do not or would not have a Material Adverse Effect. 
 (h) SEC Reports. The Company has filed all reports,
schedules, forms, statements and other documents required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for twelve (12) months preceding the date hereof (or such shorter period as the
Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC
Reports” and together with this Agreement, the “Disclosure Materials”), on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of the date hereof, the Company is not aware of any event occurring on or prior to the Closing Date (other than the transactions contemplated by the Transaction Documents) that requires the filing of a Form 8-K after the
Closing. As of their respective filing dates, or to the extent corrected by a subsequent amendment, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of
the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. 
 (i) Financial Statements. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries taken as a whole as of and for the dates thereof and the results of operations and
cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments. Each of the Material Contracts to which the Company is a party or to which the property or assets of the Company is subject
has been filed as an exhibit to the SEC Reports. 
 (j) Tax Matters. The Company (i) has prepared and filed all
foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations, except those being contested in good faith, with respect to which adequate reserves have been set aside on the books of the Company and (iii) has set aside on its books
provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply, except, in the case of clauses (i) and (ii) above, where the failure to so pay or file
any such tax, assessment, charge or return would not have a Material Adverse Effect. 
 (k) Material Changes. Since the
date of the latest financial statements included within the SEC Reports, except as specifically disclosed in the SEC Reports, (i) there have been no events, occurrences or developments that have had or would reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses and other liabilities incurred in the
ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or to be disclosed in filings made with the Commission, (iii) the
Company has not materially altered its method of accounting 

  
 9. 









 
or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or
purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company), (v) the Company has not issued any equity
securities to any officer, director or Affiliate, except Common Stock issued in the ordinary course pursuant to existing Company stock option or stock purchase plans or executive and director corporate arrangements disclosed in the SEC Reports and
(vi) there has not been any material change or amendment to, or any waiver of any material right under, any Material Contract under which the Company or any of its assets is bound or subject. Except for the issuance of the Securities
contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the Company or its business, properties, operations or financial condition that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made that has not been publicly disclosed at least one Trading Day prior to the date that this representation is made. 

(l) Environmental Matters. To the Company’s Knowledge, the Company (i) is not in violation of any statute, rule,
regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human
exposure to hazardous or toxic substances (collectively, “Environmental Laws”), (ii) does not own or operate any real property contaminated with any substance that is in violation of any Environmental Laws (iii) is
not liable for any off-site disposal or contamination pursuant to any Environmental Laws, and (iv) is not subject to any claim relating to any Environmental Laws; which violation, contamination, liability or claim has had or would have,
individually or in the aggregate, a Material Adverse Effect; and there is no pending or, to the Company’s Knowledge, threatened investigation that might lead to such a claim. 

(m) Litigation. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any
of the Transaction Documents or the Securities, (ii) involves a claim of violation of or liability under any federal, state, local or foreign laws governing the Company’s operations, including without limiting the generality of the
foregoing, laws regulating the protection of human health, including without limiting the generality of the foregoing, laws relating to the manufacture, processing, packaging, labeling, marketing, distribution, use, inspection, treatment, storage,
disposal, transport or handling of the Company’s products, and regulated or hazardous substances, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations issued, entered, promulgated or approved thereunder, all as may be in effect from time to time and all successors, replacements and expansions thereof, (iii) involves injury to or death of any person arising from
or relating to any of the Company’s product or (iv) could, if there were an unfavorable decision, individually or in the aggregate, have a Material Adverse Effect. The Commission has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act. 
 (n)
Employment Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees of the Company which would have a Material Adverse Effect. None of the Company’s employees is a
member of a union that relates to such employee’s relationship with the Company, and the Company is not a party to a collective bargaining agreement, and the Company believes that its relationship with its employees is good. 

(o) Compliance. The Company (i) is not in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company), nor has the Company received written notice of a claim that it is in default 

  
 10.









 
under or that it is in violation of, any indenture, loan or credit agreement or any other Material Contract (whether or not such default or violation has been waived), (ii) is not in
violation of any order of any court, arbitrator or governmental body having jurisdiction over the Company or its properties or assets and (iii) is not and has not been in violation of, or in receipt of notice that it is in violation of, any
statute, rule or regulation of any governmental authority applicable to the Company, including without limitation, all applicable rules and regulations of the Food and Drug Administration (the “FDA”), and all applicable laws,
statutes, ordinances, rules or regulations (including, without limitation, the Federal Food, Drug and Cosmetic Act of 1938, as amended and similar foreign laws and regulations) enforced by the FDA or equivalent foreign authorities, except in each
case as would not, individually or in the aggregate, have a Material Adverse Effect. 
 (p) Regulatory Permits. The
Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its business as described in the SEC Reports, including without limitation the FDA,
except where the failure to possess such permits, individually or in the aggregate, has not and would not have, individually or in the aggregate, a Material Adverse Effect (“Material Permits”), and (i) the Company has
not received any notice of proceedings relating to the revocation or modification of any such Material Permits and (ii) the Company is unaware of any facts or circumstances that the Company would reasonably expect to give rise to the revocation
or modification of any Material Permits. 
 (q) Title to Assets. The Company does not own any real property. The Company
has good and marketable title to all tangible personal property owned by it which is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of
such property and do not interfere with the use made and proposed to be made of such property by the Company. Any real property and facilities held under lease by the Company are held by it under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company. 
 (r) Patents and Trademarks. To the Company’s knowledge, the Company owns, possesses, licenses or has other rights to use all foreign and domestic patents, patent applications, trade and
service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology and other proprietary rights and processes (collectively, the “Intellectual Property”) necessary
for the conduct of its businesses as now conducted. Except where such violations or infringements would not have, either individually or in the aggregate, a Material Adverse Effect, to the Company’s Knowledge (a) there are no rights of
third parties to any such Intellectual Property; (b) there is no infringement by third parties of any such Intellectual Property; (c) there is no pending or threatened Action challenging the Company’s rights in or to any such
Intellectual Property; (d) there is no pending or threatened Action challenging the validity or scope of any such Intellectual Property; and (e) there is no pending or threatened Action that the Company infringes or otherwise violates any
patent, trademark, copyright, trade secret or other proprietary rights of others. 
 (s) Insurance. The Company is
insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company believes to be prudent in the businesses and locations in which the Company is engaged. The Company has not received any
notice of cancellation of any such insurance, nor does the Company have any Knowledge that it will be unable to renew its existing insurance coverage for the Company as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost. 

  
 11.









 (t) Transactions With Affiliates and Employees. None of the officers or directors of
the Company and, to the Company’s Knowledge, none of the employees of the Company, is presently a party to any transaction with the Company or to a presently contemplated transaction (other than for services as employees, officers and
directors) that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated under the Securities Act, except as contemplated by the Transaction Documents or set forth in the SEC Reports. 

(u) Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to
maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets and
liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. 
 (v) Sarbanes-Oxley; Disclosure Controls. The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it. The Company
maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act). 
 (w) Certain Fees. Other than the Placement Agent, no person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon
the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. The Company shall indemnify, pay, and hold each Purchaser harmless against,
any liability, loss or expense (including, without limitation, attorneys’ fees and out-of-pocket expenses) arising in connection with any such right, interest or claim. 
 (x) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2 of this Agreement and the accuracy of the information disclosed in
the Accredited Investor Questionnaires, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction Documents. 

(y) Registration Rights. Other than each of the Purchasers, no Person has any right to cause the Company to effect the
registration under the Securities Act of any securities of the Company other than those securities which are currently registered on an effective registration statement on file with the Commission. 

(z) No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its or its behalf has
conducted any “general solicitation” or “general advertising” (as those terms are used in Regulation D) in connection with the offer or sale of any of the Securities. 

(aa) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2, neither the Company nor any Person acting on its behalf has, directly or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security
under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or
(ii) cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior 

  
 12.









 
offerings by the Company for purposes of any applicable law, regulation or shareholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market on
which any of the securities of the Company are listed or designated. 
 (bb) Listing and Maintenance Requirements. The
Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has the Company received
any notification that the Commission is contemplating terminating such registration. 
 (cc) Investment Company. The
Company is not required to be registered as, and is not an Affiliate of, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. 
 (dd) Application of Takeover Protections; Rights Agreements. The Company and its board of directors have
taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the
Company’s charter documents or the laws of the State of Delaware that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including, without limitation, the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. The Company has not adopted a stockholder rights plan or similar
arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Company. 
 (ee)
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its SEC Reports
(including, for purposes hereof, any that are required to be disclosed in a Form 10) and is not so disclosed or that otherwise would have a Material Adverse Effect. 
 (ff) Acknowledgment Regarding the Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length
purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. 
 (gg) Foreign Corrupt
Practices. Neither the Company, nor to the Company’s Knowledge, any agent or other person acting on behalf of the Company, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of the
Foreign Corrupt Practices Act of 1977, as amended. 
 (hh) No Additional Agreements. The Company does not have any
agreement or understanding with any Purchaser with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents. 

  
 13.









 3.2 Representations and Warranties of the Purchasers. Each Purchaser hereby, for
itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date in the case of the Purchasers listed on Annex A hereto to the Company as follows: 

(a) Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of
the jurisdiction of its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution, delivery and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation, such partnership,
limited liability company or other applicable like action, on the part of such Purchaser. Each of this Agreement and the Registration Rights Agreement has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. 

(b) No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights
Agreement and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party or
(iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder. 

(c) Investment Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been
registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to, or for distributing or reselling such Securities or any part thereof in violation of
the Securities Act or any applicable state securities laws, provided, however, that by making the representations herein, such Purchaser does not agree to hold any of the Securities for any minimum period of time and reserves the right,
subject to the provisions of this Agreement and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to an effective registration statement under the Securities Act or under an
exemption from such registration and in compliance with applicable federal and state securities laws. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. Such Purchaser does not presently have any agreement,
plan or understanding, directly or indirectly, with any Person to distribute or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person or entity; such Purchaser is not a registered
broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer. 

  
 14.









 (d) Purchaser Status. At the time such Purchaser was offered the Securities, it was,
and at the date hereof it is, an “accredited investor” as defined in Rule 501(a) under the Securities Act. 
 (e)
General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or any other general advertisement. 
 (f) Experience of Such Purchaser.
Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 

(g) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Disclosure Materials and has
been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of
investing in the Securities; (ii) access to information about the Company and its respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Neither such
inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness of the Disclosure Materials
and the Company’s representations and warranties contained in the Transaction Documents. Such Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition
of the Securities. 
 (h) Certain Trading Activities. Other than with respect to the transactions contemplated herein,
since the time that such Purchaser was first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither the Purchaser nor, to the knowledge of such Purchaser, any Affiliate of such Purchaser which
(i) had knowledge of the transactions contemplated hereby, (ii) has or shares discretion relating to such Purchaser’s investments or trading or information concerning such Purchaser’s investments, including in respect of the
Securities and (iii) is subject to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has directly or indirectly, nor has any Person
acting on behalf of or pursuant to any understanding with such Purchaser or Trading Affiliate, effected or agreed to effect any transactions in the securities of the Company (including, without limitation, any Short Sales involving the
Company’s securities). Notwithstanding the foregoing, in the case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser’s or Trading Affiliate’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s or Trading Affiliate’s
assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Other than to other Persons party
to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, and except as otherwise
provided in Section 4.11, no Purchaser makes any representation, warranty or covenant hereby that it will not engage in Short Sales in the securities of the Company after the effectiveness of the Registration Statement as described in
Section 4.11. 

  
 15.









 (i) Brokers and Finders. Other than the Placement Agent, no Person will have, as a
result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered
into by or on behalf of the Purchaser. 
 (j) Independent Investment Decision. Such Purchaser has independently evaluated
the merits of its decision to purchase Securities pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s business and/or legal counsel in making such decision. Such
Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has
consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. 
 (k) Reliance on Exemptions. Such Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions from the registration requirements of United States
federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements and understandings of such Purchaser
set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. 
 (l) No Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or
endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 

(m) Regulation M. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may
apply to sales of Common Stock and other activities with respect to the Common Stock by the Purchasers. 
 (n) Residency.
Such Purchaser’s principal executive offices are in the jurisdiction set forth immediately below Purchaser’s name on the applicable signature page attached hereto. 
 (o) Trading Market. Such Purchaser acknowledges that the Securities are quoted over-the-counter, and that no securities issued by the Company are listed on a national securities exchange.

 (p) Shell Company. Such Purchaser acknowledges that the Company may be deemed to be a “shell company” as
defined by the rules and regulations of the Commission. 
 (q) Future Financings. Such Purchaser acknowledges that the
Company intends to sell and issue securities in the aggregate amount of up to ten million dollars ($10,000,000) within one hundred eighty (180) days of Closing Date in one or more financings. 

The Company and each of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or
warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction Documents. 

  
 16.









 ARTICLE 4 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions.

 (a) Compliance with Laws. Notwithstanding any other provision of this Article 4, each Purchaser covenants
that the Securities may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Securities other than (i) pursuant to an effective registration statement,
(ii) to the Company, (iii) to an Affiliate of a Purchaser, (iv) pursuant to Rule 144 (provided that the Purchaser provides the Company with reasonable assurances (in the form of seller and broker representation letters)
that the securities may be sold pursuant to such rule) or Rule 144A, (v) pursuant to Rule 144 without restriction following the applicable holding period or (vi) in connection with a bona fide pledge, the Company may require the
transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights of a
Purchaser under this Agreement and the Registration Rights Agreement. 
 (b) Legends. Certificates evidencing the
Securities shall bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form until such time as they are not required under Section 4.1(c) (and a stock transfer order
may be placed against transfer of the certificates for the Securities): 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY. 
 In addition, if any
Purchaser is an Affiliate of the Company, certificates evidencing the Securities issued to such Purchaser shall bear a customary “affiliates” legend. 
 (c) Removal of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the
applicable Shares upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account at The Depository Trust Company (“DTC”), if (i) such Securities are sold pursuant to an effective
Registration Statement and the Purchaser has delivered a signed and completed Purchaser’s Certificate of Subsequent Sale in substantially the form of Exhibit G attached hereto (the “Certificate of Sale”) with
respect to such Securities, (ii) such Securities are sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of the Company) or (iii) such Securities are eligible for sale under Rule 144 without restriction.
Any fees (with respect to the Transfer Agent, Company Counsel 

  
 17.









 
or otherwise) associated with the removal of such legend shall be borne by the Company. Following such time as a legend is no longer required for certain Securities, the Company will no later
than three (3) Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent (with notice to the Company) of a legended certificate representing such Shares (endorsed or with stock powers attached, signatures
guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer), deliver or cause to be delivered to the transferee of such Purchaser or such Purchaser, as applicable, a certificate representing such Securities that is free
from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.1. Certificates for Shares subject to
legend removal hereunder may be transmitted by the Transfer Agent to the Purchasers, as applicable, by crediting the account of the transferee’s Purchaser’s prime broker with DTC. 

(d) Irrevocable Transfer Agent Instructions. The Company shall issue irrevocable instructions to its Transfer Agent, and any
subsequent Transfer Agent, in the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent Instructions”). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent
Instructions or instructions consistent therewith referred to in this Section 4.1(d) will be given by the Company to its Transfer Agent in connection with this Agreement, and that the Securities shall otherwise be freely transferable on the
books and records of the Company as and to the extent provided in this Agreement, the other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this Section 4.1(d) will cause
irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 4.1(d) will be inadequate and agrees, in the event of a breach or threatened breach by the Company
of the provisions of this Section 4.1(d), that a Purchaser shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity
of showing economic loss and without any bond or other security being required. 
 (e) Acknowledgement. Each Purchaser
hereunder acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Shares or any interest therein without complying with the requirements of the Securities Act. While the Registration
Statement remains effective, each Purchaser hereunder may sell the Shares in accordance with the plan of distribution contained in the Registration Statement and, if it does so, it will comply therewith and with the related prospectus delivery
requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other Purchasers, agrees that if it is notified by the Company in writing at any time that the Registration Statement registering the resale
of the Shares is not effective or that the prospectus included in such Registration Statement no longer complies with the requirements of Section 10 of the Securities Act, the Purchaser will refrain from selling such Shares until such time as
the Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant with Section 10 of the Exchange Act, unless such Purchaser is able to, and does, sell such Shares pursuant to an available
exemption from the registration requirements of Section 5 of the Securities Act. 
 4.2 Acknowledgment of Dilution.
The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock. The Company further acknowledges that its obligations under the Transaction Documents, including without limitation its
obligation to issue the Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company
may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company. 

  
 18.









 4.3 Antidilution Adjustment. As to each Purchaser, during the one hundred eighty days
(180) days following the Closing Date, if any issuance, sale, grant of any option or right to purchase or other disposition of any equity security or any equity-linked or related security (including, without limitation, any “equity
security” (as that term is defined under Rule 405 promulgated under the Securities Act), any securities convertible into such equity securities, any preferred stock or any purchase rights) is for a consideration per share that is less
than the Purchase Price (adjusted for stock splits, combinations, dividends and the like occurring after the date hereof) (such lesser price is referred to herein as the “Discounted Purchase Price”) (the foregoing, a
“Dilutive Issuance”), other than the Excluded Securities (as defined below), then immediately after such Dilutive Issuance, the Company shall issue to such Purchaser solely with respect to the Shares acquired pursuant to this
Agreement or in connection with a Dilutive Issuance, without the payment of additional consideration, in connection with such Dilutive Issuance, a number of additional shares of Common Stock (the “Additional Shares”) equal to
the result of subtracting (B) from (A) where (A) is the number of shares of Common Stock the Buyer would have received if the Buyer had paid the Discounted Purchase Price instead of the Purchase Price (adjusted for stock splits,
combinations, dividends and the like occurring after the Closing Date), and (B) is the number of shares of Common Stock initially issued to the Purchaser at the Closing (adjusted for stock splits, combinations, dividends and the like occurring
after the Closing Date) plus any shares of Common Stock previously received by Purchaser under this Section in respect of a Dilutive Issuance (adjusted for stock splits, combinations, dividends and the like occurring after the Closing
Date). Upon any issuance of Additional Shares hereunder, such Additional Shares shall be included as Registrable Securities (as defined in the Registration Rights Agreement). 

Excluded Securities include: (a) shares of Common Stock issued upon conversion of any convertible securities outstanding as of the
date hereof; (b) shares of Common Stock or securities convertible into Common Stock issued to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary pursuant to stock purchase agreements, stock option
plans or other arrangements that are approved by the Company’s board of directors; (c) shares of Common Stock or securities convertible into Common Stock issued in connection with strategic transactions involving the Company and other
entities approved by the Company’s board of directors; and (d) shares of Common Stock or securities convertible into Common Stock that the holders of a majority of the outstanding Shares elect in writing to deem Excluded Securities.

 4.4 Furnishing of Information. In order to enable the Purchasers to sell the Securities under Rule 144 of the
Securities Act, for a period of one year from the Closing Date, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be
filed by the Company after the date hereof pursuant to the Exchange Act. During such one year period, if the Company is not required to file reports pursuant to such laws, it will prepare and furnish to the Purchasers and make publicly available in
accordance with Rule 144(c) such information as is required for the Purchasers to sell the Shares under Rule 144. 
 4.5
Form D and Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Purchaser who requests a copy in writing promptly after such
filing. The Company, on or before the Closing Date, shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to the Purchasers at the Closing pursuant to
this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Purchasers who request in
writing such evidence on or prior to the Closing Date. The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the United
States following the Closing Date. 

  
 19.









 4.6 No Integration. The Company shall not, and shall use its commercially reasonable
efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or
sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. 

4.7 Securities Laws Disclosure; Publicity. By 9:00 a.m., New York City time, on the Trading Day immediately following the
execution of this Agreement, the Company shall issue a press release (the “Press Release”) disclosing all material terms of the transactions contemplated hereby. On or before 9:00 a.m., New York City time, on the second
Trading Day following the execution of this Agreement (or such earlier time as required by law), the Company will file a Current Report on Form 8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to
such Current Report on Form 8-K the material Transaction Documents (including, without limitation, this Agreement and the Registration Rights Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser or an Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or Trading Market,
without the prior written consent of such Purchaser, except (i) as required by federal securities law in connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final
Transaction Documents (including signature pages thereto) with the Commission or (ii) to the extent such disclosure is required by law, request of the Staff of the Commission or Trading Market regulations, in which case the Company shall
provide the Purchasers with prior written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received from the
Company or any of its respective officers, directors, employees or agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. Each
Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in this Section 4.7, such Purchaser will
maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). 
 4.8 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company shall not and shall cause each of its
officers, directors, employees and agents, not to, provide any Purchaser with any material, non-public information regarding the Company from and after the filing of the Press Release without the express written consent of such Purchaser, unless
prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. 

4.9 Indemnification. 
 (a) Indemnification of the Purchasers. In addition to the indemnity provided in the Registration Rights Agreement, the Company will indemnify and hold each Purchaser and its directors, officers,
shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such 

  
 20.









 
titles notwithstanding a lack of such title or any other title) of such controlling person (each, a “Purchaser Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur, as a
result of or relating to third party claims against such Purchaser relating to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, provided
that that such a claim for indemnification relating to any breach of any of the representations or warranties made by the Company in this Agreement is made within one (1) year from the Closing. The Company will not be liable to any Purchaser
Party under this Agreement to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser
Party in this Agreement or in the other Transaction Documents. 
 (b) Conduct of Indemnification Proceedings.
Promptly after receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding or investigation in
respect of which indemnity may be sought pursuant to Section 4.9(a), such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably
satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be
at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding
and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. Without
the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified
Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding.

 4.10 Listing of Securities. In the time and manner required by the Principal Trading Market, the Company shall prepare
and file with such Trading Market an additional shares listing application covering all of the Shares and shall use its commercially reasonable efforts to take all steps necessary to maintain, so long as any other shares of Common Stock shall be so
listed, such listing. 
 4.11 Use of Proceeds. The Company intends to use the net proceeds from the sale of the
Securities hereunder for working capital and general corporate purposes. 
 4.12 Dispositions and Confidentiality After The
Date Hereof. Each Purchaser shall not, and shall cause its Trading Affiliates not to, prior to the effectiveness of the Registration Statement: (a) sell, offer to sell, solicit offers to buy, dispose of, loan, pledge or grant any right with
respect to (collectively, a “Disposition”) the Securities; or (b) engage in any hedging or other transaction which is designed or could reasonably be expected to lead to or result in a Disposition of the Securities by
such Purchaser or an Affiliate, except, in each case, for Dispositions pursuant to an available exemption from, or in a 

  
 21.









 
transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws. In addition, the Purchaser agrees that
for so long as it owns any Common Stock, it will not enter into any short sale of Shares executed at a time when the Purchaser has no equivalent offsetting long position in the Common Stock. For purposes of determining whether the Purchaser has an
equivalent offsetting long position in the Common Stock, shares that the Purchaser is entitled to receive within sixty (60) days (whether pursuant to contract or upon conversion or exercise of convertible securities) will be included as if held
long by the Purchaser. Such Purchaser covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage in any transactions in the Company’s securities (including, without limitation, any Short
Sales involving the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced as described in Section 4.7 or
(ii) this Agreement is terminated in full pursuant to Section 6.17. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such
Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall apply only with
respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Each Purchaser understands and acknowledges, severally and not jointly with any other Purchaser,
that the Commission currently takes the position that covering a short position established prior to effectiveness of a resale registration statement with shares included in such registration statement would be a violation of Section 5 of the
Securities Act, as set forth in Division of Corporation Financing Compliance and Disclosure Interpretation 239.10 regarding short selling. 
 4.13 Future Registration Statements. Except for a registration statement on Form S-8 relating to the Company’s stock option plan, during the one hundred eighty days (180) days following
the Closing Date, the Company shall not file a registration statement with the SEC to register for resale the shares of common stock received by its stockholders in the Reverse Merger Transaction. 

ARTICLE 5 

CONDITIONS PRECEDENT TO CLOSING 
 5.1 Conditions Precedent to the Obligations of the Purchasers to Purchase Securities at the Closing. The obligation of each Purchaser listed on Annex A hereto to acquire Securities at the
Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by such Purchaser (as to itself only): 

(a) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct
in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made and as of the
Closing Date, as though made on and as of such date, except for such representations and warranties that speak as of a specific date. 
 (b) Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be
performed, satisfied or complied with by it at or prior to the Closing. 
 (c) No Injunction. No statute, rule,
regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents. 

  
 22.









 (d) Consents. The Company shall have obtained in a timely fashion any and all
consents, permits, approvals, registrations and waivers necessary for consummation of the purchase and sale of the Securities at the Closing (including all Required Approvals), all of which shall be and remain so long as necessary in full force and
effect. 
 (e) No Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the
Closing Date, by the Commission. 
 (f) Company Deliverables. The Company shall have delivered the Company Deliverables
in accordance with Section 2.2(a). 
 (g) Compliance Certificate. The Company shall have delivered to each Purchaser
a certificate, dated as of the Closing Date and signed by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in Sections 5.1(a) and (b) in the
form attached hereto as Exhibit F. 
 (h) Lock-Up Agreements. The officers and directors of the Company and
certain stockholders of the Company shall have delivered lock-up agreements in the form attached hereto as Exhibit H. 

(i) Completion of the Reverse Merger Transaction. The Reverse Merger Transaction shall have been completed. 

(j) Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with Section 6.17 herein.

 5.2 Conditions Precedent to the Obligations of the Company to sell Securities at the Closing. The Company’s
obligation to sell and issue the Securities to each Purchaser listed on Annex A hereto at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which
may be waived by the Company: 
 (a) Representations and Warranties. The representations and warranties made by such
Purchaser in Section 3.2 hereof shall be true and correct in all material respects as of the date when made, and as of the Closing Date as though made on and as of such date, except for representations and warranties that speak as of a specific
date. 
 (b) Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date. 
 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of
competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. 

(d) Purchaser Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).


  
 23.









 (e) Completion of the Reverse Merger Transaction. The Reverse Merger Transaction
shall have been completed. 
 (f) Termination. This Agreement shall not have been terminated as to such Purchaser in
accordance with Section 6.17 herein. 
 ARTICLE 6 

MISCELLANEOUS 
 6.1 Fees and Expenses. Except as set forth in this Section 6.1, the Company and the Purchasers shall each pay the fees and expenses of their respective advisers, counsel, accountants and other
experts, if any, and all other expenses incurred by such party in connection with the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and
duties levied in connection with the sale and issuance of the Securities to the Purchasers. 
 6.2 Entire Agreement. The
Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and
deliver to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction Documents. 
 6.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of
(a) the date of transmission, if such notice or communication is delivered via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this Section prior to 5:00
p.m., New York City time, on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section on a day that is not a Trading Day
or later than 5:00 p.m., New York City time, on any Trading Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual
receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 
  

			
	If to the Company:	  	Lipocine Inc.
		  	675 Arapeen Drive
		  	Suite 202
		  	Salt Lake City, Utah 84108
		  	Telephone No.: (801) 994-7383
		  	Facsimile No.: (801) 994-7388
		  	Attention: Robert Merrell
		
	With a copy to:	  	Cooley LLP
		  	3175 Hanover Street
		  	Palo Alto, California 94304-1130
		  	Telephone No.: (650) 843-5000
		  	Facsimile No.: (650) 849-7400
		  	Attention: John T. McKenna


  
 24.










			
		
	If to a Purchaser:	  	 To the address set forth under such Purchaser’s name on
 the signature page hereof;

		
		  	 or such other address as may be designated in writing
 hereafter, in the same manner, by such Person.


 6.4 Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived
or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire 66 2/3% of the Shares purchased at Closing or, in the case of a waiver, by the party against whom
enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of
any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser to
amend or consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also offered to all Purchasers who then hold Securities. 

6.5 Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This
Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction
Documents. 
 6.6 Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding
upon the parties and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the prior written consent of the Purchasers. Any Purchaser may assign its rights
hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and applicable law, provided such transferee shall agree in writing to be bound, with respect to the
transferred Securities, by the terms and conditions of this Agreement that apply to the “Purchasers”. 

6.7 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 
 6.8
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to
the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to
assert in any Proceeding, 

  
 25.









 
any claim that it is not personally subject to the jurisdiction of any such New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto
hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY. 
 6.9 Survival. The representations and warranties contained herein shall survive
the Closing and the delivery of the Securities for a period of one (1) year from the Closing Date. The agreements and covenants contained herein shall survive for the applicable statute of limitations. 

6.10 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission, or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile signature page were an original thereof. 
 6.11 Severability. If any
provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will
attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 

6.12 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or
destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and the
Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs associated with the issuance of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation thereof, the Company may require delivery of such
mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 
 6.13 Remedies. In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree
that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other
than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate. 

  
 26.









 6.14 Payment Set Aside. To the extent that the Company makes a payment or payments to
any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to
be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy
law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred. 
 6.15 Adjustments in Share Numbers and
Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common
Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such
event. 
 6.16 Independent Nature of the Purchasers’ Obligations and Rights. The obligations of each Purchaser under
any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The
decision of each Purchaser to purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business,
affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser,
and no Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained herein or in any
Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with
making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled
to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any proceeding for such purpose. The Company acknowledges that each of the Purchasers has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Purchasers and not because it was required or
requested to do so by any Purchaser. The Company’s obligations to each Purchaser under this Agreement are identical to its obligations to each other Purchaser other than such differences resulting solely from the number of Securities purchased
by such Purchaser, but regardless of whether such obligations are memorialized herein or in another agreement between the Company and a Purchaser. 
 6.17 Termination. This Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to the Closing by either the Company or any Purchaser listed on Annex A
hereto (with respect to itself only), upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m., New York City time, on the Outside Date; provided, however, that the right to terminate this Agreement
under this Section 6.17 shall not be available to any Person whose 

  
 27.









 
failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this Section 6.17
shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other
party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this Section, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this
Section, the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction
Documents as a result therefrom. 
 6.18 Rescission and Withdrawal Right. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option owed to such Purchaser by the Company under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then, prior to the performance by the Company of the Company’s related obligation, such Purchaser may rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
 [SIGNATURE PAGES FOR PURCHASERS
FOLLOW] 

  
 28.









 IN WITNESS WHEREOF, the parties hereto
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	LIPOCINE INC.
		
	By:	 	 /s/ Mahesh V. Patel, Ph.D.

		 	Mahesh V. Patel, Ph.D.
		 	President and Chief Executive Officer



  
 1. 









 OMNIBUS SIGNATURE PAGE TO PURCHASE AGREEMENT AND REGISTRATION 

RIGHTS AGREEMENT OF LIPOCINE INC. 
 IN WITNESS WHEREOF, the undersigned Purchaser hereby executes, delivers, joins in and agrees to be bound by (i) (A) the Securities Purchase Agreement by and between Lipocine Inc. and the
Purchasers (as defined therein) to which this Omnibus Signature Page is attached as an Purchaser thereunder and (B) the Registration Rights Agreement, attached to the Securities Purchase Agreement, by and among the Company and the Purchaser,
which, together with all counterparts of such agreements and signature pages of other parties to such agreements, shall constitute one and the same document in accordance with the terms of such agreements, and (ii) elects to purchase for the
number of Shares set forth below. 
  

			
	NAME OF PURCHASER:	 	  




 

			
	By:	 	  

	Name:	 	  

	Title:	 	  




 

			
	Aggregate Purchase Price (Subscription Amount):
	$                    	 	


  

			
	Number of Shares to be Acquired:	 	  




 

			
	Tax ID No.:	 	  




 

			
	Address for Notice:
	
	  

	  




 

			
	Telephone No.:	 	  



 

			
		
	Facsimile No.:	 	  



 

			
		
	Attention:	 	  



  

			
	Delivery Instructions:
	(if different than above)


			
		
	c/o	 	  



			
		
	Street:	 	  



			
		
	City/State/Zip:	 	  



			
		
	Attention:	 	  



			
		
	Telephone No.:	 	  



  
 2. 









 ANNEX A: Schedule of Purchasers 
 EXHIBITS: 
  

			
	A:	  	Form of Registration Rights Agreement
	B-1:	  	Accredited Investor Questionnaire
	B-2:	  	Stock Certificate Questionnaire
	C:	  	Form of Opinion of Company Counsel
	D:	  	Irrevocable Transfer Agent Instructions
	E:	  	Form of Secretary’s Certificate
	F:	  	Form of Officer’s Certificate
	G:	  	Purchaser’s Certificate of Subsequent Sale
	H:	  	Form of Lock-Up Agreement


  
 3. 









 ANNEX A 
 SCHEDULE OF PURCHASERS 
  

									
	 Purchasers
	  	Number
of Shares
Purchased	 	  	Purchase Price	 
	 Visium Balanced Master Fund, Ltd.
	  	 	1,206,000	  	  	$	7,236,000.00	  
	 Janus Global Life Sciences Fund, a Series of Janus Investment Fund
	  	 	833,333	  	  	$	4,999,998.00	  
	 Cormorant Global Healthcare Master Fund, LP
	  	 	666,666	  	  	$	3,999,996.00	  
	 Sabby Healthcare Volatility Master Fund, Ltd.
	  	 	500,000	  	  	$	3,000,000.00	  
	 Baker Brothers Life Sciences, L.P.
	  	 	436,555	  	  	$	2,619,330.00	  
	 Armistice Capital Master Fund Ltd.
	  	 	333,334	  	  	$	2,000,004.00	  
	 1798 Fundamental Strategies Master Fund Ltd.
	  	 	333,333	  	  	$	1,999,998.00	  
	 Broadfin Healthcare Master Fund, Ltd.
	  	 	333,333	  	  	$	1,999,998.00	  
	 Del Mar Master Fund Ltd.
	  	 	333,333	  	  	$	1,999,998.00	  
	 Three Arch Opportunity Fund LP
	  	 	250,000	  	  	$	1,500,000.00	  
	 RTW Master Fund, Ltd.
	  	 	208,333	  	  	$	1,249,998.00	  
	 DAFNA Lifescience Select Ltd.
	  	 	159,500	  	  	$	957,000.00	  
	 Monashee Investment Management LLC
	  	 	150,000	  	  	$	900,000.00	  
	 2B LLC
	  	 	80,000	  	  	$	480,000.00	  
	 ProSight Fund, LP
	  	 	75,000	  	  	$	450,000.00	  
	 DAFNA Lifescience Ltd.
	  	 	71,000	  	  	$	426,000.00	  
	 The Entrust Group Inc. FBO Kevin Paul Beck IRA #50-01463
	  	 	58,333	  	  	$	349,998.00	  
	 Hartz Capital Investments LLC
	  	 	42,000	  	  	$	252,000.00	  
	 Russell P. Shipman
	  	 	41,667	  	  	$	250,002.00	  
	 Thomas Robert Malley
	  	 	41,667	  	  	$	250,002.00	  
	 Edward F. Keely
	  	 	41,666	  	  	$	249,996.00	  
	 667, L.P. (Account #1)
	  	 	31,042	  	  	$	186,252.00	  
	 Jay Silverman
	  	 	25,000	  	  	$	150,000.00	  
	 667, L.P. (Account #2)
	  	 	21,578	  	  	$	129,468.00	  
	 DAFNA Lifescience Market Neutral Ltd.
	  	 	19,500	  	  	$	117,000.00	  
	 Empery Asset Master, Ltd.
	  	 	17,000	  	  	$	102,000.00	  
	 Jon-Erik Borgen
	  	 	16,666	  	  	$	99,996.00	  
	 14159, L.P.
	  	 	10,825	  	  	$	64,950.00	  
		  	  
	  
	 	  	  
	  
	 
	 Total
	  	 	6,336,664	  	  	$	38,019,984.00	  
		  	  
	  
	 	  	  
	  
	 


  
 4. 









 EXHIBIT A 
 FORM OF REGISTRATION RIGHTS AGREEMENT 

  
 5. 









 INSTRUCTION SHEET 

(TO BE READ IN CONJUNCTION WITH THE ENTIRE SECURITIES PURCHASE 

AGREEMENT AND REGISTRATION RIGHTS AGREEMENT) 
  

	A.	Complete the following items in the Securities Purchase Agreement and/or Registration Rights Agreement: 


 

	 	1.	Provide the information regarding the Purchaser requested on the signature pages. The Securities Purchase Agreement and the Registration Rights Agreement (omnibus
signature page) must be executed by an individual authorized to bind the Purchaser. 

  

	 	2.	Exhibit B-1 – Accredited Investor Questionnaire: 

 Provide the information requested by the Accredited Investor Questionnaire 
  

	 	3.	Exhibit B-2 Stock Certificate Questionnaire: 

 Provide the information requested by the Stock Certificate Questionnaire 
  

	 	4.	Annex B to the Registration Rights Agreement — Selling Securityholder Notice and Questionnaire 


Provide the information requested by the Selling Securityholder Notice and Questionnaire 

 

	 	5.	Return the signed Securities Purchase Agreement and Registration Rights Agreement (omnibus signature page) to: 


Vlad Ivanov 

Ladenburg Thalmann & Co. Inc 
 520 Madison Avenue, 9th Floor 
 New York, NY 10022 

Tel: (212) 409-2045 
 Fax: (718) 986-8496 
 Email: vivanov@ladenburg.com 

 

	B.	Instructions regarding the transfer of funds for the purchase of the Securities are contained in the Escrow Deposit Agreement with Signature Bank, a New York State
chartered bank, which instructions have been provided to the purchasers. 


  
 6. 









 EXHIBIT B-1 
 ACCREDITED INVESTOR QUESTIONNAIRE 
 (ALL INFORMATION WILL BE TREATED
CONFIDENTIALLY) 
 To: Lipocine Inc. 
 This Investor Questionnaire (“Questionnaire”) must be completed by each potential investor in connection with the offer and sale of the shares of the common stock, par value $0.001
per share, and shares of common stock that may be issued upon exercise of certain warrants (collectively, the “Securities”), of Lipocine Inc., a Delaware corporation (the “Corporation”). The Securities
are being offered and sold by the Corporation without registration under the Securities Act of 1933, as amended (the “Act”), and the securities laws of certain states, in reliance on the exemptions contained in
Section 4(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The Corporation must determine that a potential investor meets certain suitability requirements before
offering or selling Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether
you meet such criteria, and reliance upon the private offering exemptions from registration is based in part on the information herein supplied. 
 This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly confidential. However, by signing this Questionnaire, you will
be authorizing the Corporation to provide a completed copy of this Questionnaire to such parties as the Corporation deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation of the Act or the
securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of the Securities. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire. Please
print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item. 
  

	PART A.	BACKGROUND INFORMATION 

  

			
	Name of Beneficial Owner of the Securities:	 	  


  

			
	Business Address:	 	  

		 	(Number and Street)

  

					
	  

	(City)	  	(State)	  	(Zip Code)

  

							
	Telephone Number:	 	 (        )
	 		 	

 If a corporation, partnership, limited liability company, trust or other entity: 

 

			
	Type of entity:	 	  



			
		
	State of formation:	 	  



			
		
	Approximate Date of formation:	 	  



  
 7. 









 Set forth in the space provided below the (i) state(s), if any, in the United States in which you
maintained your principal office during the past two years and the dates during which you maintained your office in each state, and (ii) state(s), if any, in which you pay income taxes: 

 

	
	  

	
	  

	
	  


 Were you formed for the purpose of investing in the securities being offered? 

 

			
	 Yes         
	  	No         

 If an individual: 
  

			
	Residence Address:	 	  

		 	(Number and Street)

  

					
	  

	(City)	  	(State)	  	(Zip Code)

  

							
	Telephone Number:	 	 (        )
	 		 	

  

															
	Age:	 	  
	 		 	Citizenship:	 	  
	 		 	Where registered to vote:	 	  


 Set forth in the space provided below the state(s), if any, in the United States in which you maintained your residence
during the past two years and the dates during which you resided in each state: 
 Are you a director or executive officer of the Corporation?

  

					
	 Yes         
	  	No         	  	

  

			
	Social Security or Taxpayer Identification No.	 	  


 PART B. ACCREDITED INVESTOR QUESTIONNAIRE 
 In order for the Company to offer and sell the Securities in conformance with state and federal securities laws, the following information must be obtained regarding your investor status. Please initial
each category applicable to you as a Purchaser of Securities of the Company. 
  

					
	        	  	(1)	  	A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether
acting in its individual or fiduciary capacity;
			
	        	  	(2)	  	A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;
			
	        	  	(3)	  	An insurance company as defined in Section 2(13) of the Securities Act;


  
 8. 










					
			
	        	  	(4)	  	An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act;
			
	        	  	(5)	  	A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;
			
	        	  	(6)	  	A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its
employees, if such plan has total assets in excess of $5,000,000;
			
	        	  	(7)	  	An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section
3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment
decisions made solely by persons that are accredited investors;
			
	        	  	(8)	  	A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
			
	        	  	(9)	  	An organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for the specific
purpose of acquiring the Securities, with total assets in excess of $5,000,000;
			
	        	  	(10)	  	An executive officer or director of the Company;
			
	        	  	(11)	  	A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 (for purposes of this calculation, do
not include your primary residence as an asset, and do not include as a liability indebtedness that is secured by your primary residence that is not in excess of the fair market value of your primary residence (except that if the amount of such
indebtedness outstanding at the time of sale of the Securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a
liability);
			
	        	  	(12)	  	A natural person who had an individual income in excess of $200,000 in each of the two most recent years, or joint income with that person’s spouse in excess of $300,000, in
each of those years, and has a reasonable expectation of reaching the same income level in the current year;
			
	        	  	(13)	  	A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person who has
such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of investing in the Company;
			
	        	  	(14)	  	An entity in which all of the equity owners qualify under any of the above subparagraphs. If the undersigned belongs to this investor category only, list the equity owners of the
undersigned, and the investor category which each such equity owner satisfies:


  
 9. 









 (Continue on a separate piece of paper, if necessary.) 

 

	A.	FOR EXECUTION BY AN INDIVIDUAL: 

  

									
	Date	 	  
	 		 	By:	 	  

					
		 		 		 	Print Name:	 	  




 

	B.	FOR EXECUTION BY AN ENTITY: 

  

									
		 		 		 	Entity Name:	 	  

					
	Date	 	  
	 		 	By	 	  

					
		 		 		 	Print Name:	 	  

					
		 		 		 	Title:	 	  




 

	C.	ADDITIONAL SIGNATURES (if required by partnership, corporation or trust document): 


 

									
		 		 		 	Entity Name:	 	  

					
	Date	 	  
	 		 	By	 	  

					
		 		 		 	Print Name:	 	  

					
		 		 		 	Title:	 	  

					
		 		 		 	Entity Name:	 	  

					
	Date	 	  
	 		 	By	 	  

					
		 		 		 	Print Name:	 	  

					
		 		 		 	Title:	 	  




  
 10.









 EXHIBIT B-2 
 STOCK CERTIFICATE QUESTIONNAIRE 
 Pursuant to Section 2.2(b) of the
Agreement, please provide us with the following information: 
  

	1.	The exact name that the Securities are to be registered in (this is the name that will appear on the stock certificate(s)). You may use a nominee name if appropriate:


  

	
	  

	  



  

	2.	The relationship between the Purchaser of the Securities and the Registered Holder listed in response to Item 1 above: 


 

	
	  

	  



  

	3.	The mailing address, telephone and telecopy number of the Registered Holder listed in response to Item 1 above: 


 

	
	  

	  

	  

	  



  

	4.	The Tax Identification Number (or, if an individual, the Social Security Number) of the Registered Holder listed in response to Item 1 above:


  

	
	  

	  




  
 11.









 EXHIBIT C 
 FORM OF OPINION OF COMPANY COUNSEL 
 To be separately provided. 

  
 12.









 EXHIBIT D 
 Form of Irrevocable Transfer Agent Instructions 
 As of July 26, 2013

 Globex Transfer, LLC 
 Transfer
Agent and Registrar 
 780 Deltona Boulevard, Suite 202 
 Attn: Michael Turner 
 Ladies and Gentlemen: 

Reference is made to that certain Securities Purchase Agreement, dated as of July 26, 2013 (the
“Agreement”), by and among Lipocine Inc., a Delaware corporation (the “Company”), and the purchasers named on the signature pages thereto (collectively, and including permitted transferees, the
“Holders”), pursuant to which the Company is issuing to the Holders shares (the “Shares”) of Common Stock of the Company, par value $0.0001 per share (the “Common Stock”), which
are exercisable into shares of Common Stock. 
 This letter shall serve as our irrevocable authorization and direction to you
(provided that you are the transfer agent of the Company at such time and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you from time to time, if any, to issue certificates
representing shares of Common Stock upon transfer or resale of the Shares. 
 You acknowledge and agree that so long as you have
received (a) written confirmation from the Company’s legal counsel that a registration statement covering resales of the Shares has been declared effective by the Securities and Exchange Commission (the
“Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), a copy of such registration statement and a completed and signed Purchaser’s Certificate of Subsequent Sale with
respect to a sale pursuant to such effective registration statement, (b) written confirmation from the Company’s legal counsel that the Shares are eligible for sale in conformity with Rule 144 under the Securities Act (“Rule
144”) and customary documentation from a Holder’s broker with respect to a sale pursuant to Rule 144 or (c) written confirmation from the Company’s legal counsel that the Shares are eligible for sale without restriction
in conformity with Rule 144, then, unless otherwise required by law, within five (5) business days of your receipt of a notice of sale and documentation required pursuant to clause (a) or (b) above, as applicable, or a request from a
Holder for the issuance of an unlegended certificate in the event that the Shares are eligible for sale without restriction in conformity with Rule 144 under the Securities Act, you shall issue the certificates representing the Shares, as the case
may be, registered in the names of the purchaser of such Shares or the Holder, as the case may be, and such certificates shall not bear any legend restricting transfer of the Shares thereby and should not be subject to any stop-transfer restriction.

 In the event that you have not received the documentation required pursuant to clause (a) or (b) of the immediately
preceding paragraph or such Shares are not eligible for sale without restriction in conformity with Rule 144 under the Securities Act, then the certificates for such Shares shall bear the following legend: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED 

  
 13.









 
OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY. 

Please be advised that the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each
Holder is a third party beneficiary to these instructions. 
 Please execute this letter in the space indicated to acknowledge
your agreement to act in accordance with these instructions. 
  

			
	Very truly yours,
	
	LIPOCINE INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  



  

			
	Acknowledged and Agreed:
	
	GLOBEX TRANSFER LLC
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	Date:	 	 July     , 2013



  
 14.









 EXHIBIT E 
 FORM OF SECRETARY’S CERTIFICATE 
 The undersigned hereby certifies
that he is the duly elected, qualified and acting Secretary of Lipocine Inc., a Delaware corporation (the “Company”), and that as such he is authorized to execute and deliver this certificate in the name and on behalf of the
Company and in connection with the Securities Purchase Agreement, dated as of July 26, 2013, by and among the Company and the Purchasers party thereto (the “Securities Purchase Agreement”), and further certifies in his
official capacity, in the name and on behalf of the Company, the items set forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase Agreement. 

1. Attached hereto as Exhibit A is a true, correct and complete copy of the resolutions duly adopted by the Board of Directors of
the Company at a meeting of the Board of Directors held on July 24, 2013. Such resolutions have not in any way been amended, modified, revoked or rescinded, have been in full force and effect since their adoption to and including the date
hereof and are now in full force and effect. 
 2. Attached hereto as Exhibit B is a true, correct and complete copy of
the Certificate of Incorporation of the Company, together with any and all amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Certificate of Incorporation, the same being in full force and
effect in the attached form as of the date hereof. 
 3. Attached hereto as Exhibit C is a true, correct and complete
copy of the Bylaws of the Company and any and all amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect in the attached form as of the date
hereof. 
 4. Each person listed below has been duly elected or appointed to the position(s) indicated opposite his name and is
duly authorized to sign the Securities Purchase Agreement and each of the Transaction Documents on behalf of the Company, and the signature appearing opposite such person’s name below is such person’s genuine signature. 

 

					
	 Name
	 	 Position
	 	 Signature

			
	Mahesh V. Patel, Ph.D.	 	President and Chief Executive Officer	 	  

			
	Robert K. Merrell	 	Vice President, Finance	 	  



  
 15.









 IN WITNESS
WHEREOF, the undersigned has hereunto set his hand as of this 30th day of July, 2013. 
  

	
	  

	Gordhan Patel, R. Ph.
	Secretary


 I, Mahesh V. Patel, Ph.D., President and Chief Executive Officer, hereby certify that Gordhan
Patel, R. Ph. is the duly elected, qualified and acting Secretary of the Company and that the signature set forth above is his true signature. 
  

	
	  

	Mahesh V. Patel, Ph.D.
	President and Chief Executive Officer



  
 16.









 EXHIBIT A 

RESOLUTIONS 

  
 17.









 EXHIBIT B 

CERTIFICATE OF INCORPORATION 

  
 18.









 EXHIBIT C 

BYLAWS 

  
 19.









 EXHIBIT F 
 FORM OF OFFICER’S CERTIFICATE 
 The undersigned President and Chief
Executive Officer of Lipocine Inc., a Delaware corporation (the “Company”), pursuant to Section 5.1(g) of the Securities Purchase Agreement, dated as of July 30, 2013, by and among the Company and the Purchasers
signatory thereto (the “Agreement”), hereby represents, warrants and certifies to such investors as follows (capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement):

 1. The representations and warranties of the Company contained in the Agreement are true and correct in all material respects
(except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties are true and correct in all respects) as of the date when made and as of the Closing Date, as though made on
and as of such date, except for such representations and warranties that speak as of a specific date. 
 2. The Company has
performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing. 

IN WITNESS WHEREOF, the undersigned has executed this
certificate this 30th day of July, 2013. 

 

	
	  

	Mahesh V. Patel, Ph.D.
	President and Chief Executive Officer



  
 20.









 EXHIBIT G 
 PURCHASER’S CERTIFICATE OF SUBSEQUENT SALE 
  

					
	To:	  	 Sale Kwon
 Cooley
LLP
 3175 Hanover Street

Palo Alto, California 94304-1130
	  	
			
		  	 Tel: (650) 843-5981
 Fax:
(650) 849-7400
 Email: skwon@cooley.com
	  	

 The undersigned, the selling securityholder or an officer of, or other duly authorized person, hereby
certifies that                      represents that it has sold
                 shares of the Common Stock of Lipocine Inc. and that such shares were sold on
                     either (i) in accordance with the registration statement on Form S-1 with file number
                    , in which case the selling securityholder certifies that such selling securityholder has delivered a current prospectus in
connection with such sale, provided, however, that if Rule 172 under the Securities Act of 1933, as amended, is then in effect, such selling securityholder has confirmed that a current prospectus is deemed to be delivered in connection with such
sale, or (ii) in accordance with Rule 144 under the Securities Act of 1933 ( “Rule 144”), in which case the selling securityholder certifies that it has complied with the requirements of Rule 144. Print or type:

  

							
	Name of individual representing selling securityholder (if an institution):	 		 	  

			
	Title of individual representing selling securityholder (if an institution):	 		 	  

			
	Signature by:	 		 	  

				
	Selling securityholder or individual representative:	 		 	By:	 	  

				
		 		 	Name:	 	  

				
		 		 	Title:	 	  



  
 21.









 EXHIBIT H 
 FORM OF LOCK-UP AGREEMENT 
 LOCK-UP AGREEMENT 

June 30, 2013 
 Ladenburg
Thalmann & Co. 
 520 Madison Avenue 
 New York, New York 10022 
 Ladies & Gentlemen: 

The undersigned is an owner of record or beneficially of certain shares of common stock, par value $0.01 per share, of Lipocine, Inc.
(the “Company” and the “Shares”) or securities convertible into or exchangeable or exercisable for Shares. The Company proposes to carry out a private offering of Shares (the “Offering”) for which
Ladenburg Thalmann & Co. Inc. will act as placement agent (the “Placement Agent”). The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit the Company by, among other things,
raising additional capital for its operations. The undersigned acknowledges that the Company and the Placement Agent are relying on the representations and agreements of the undersigned contained in this letter agreement in carrying out the
Offering. 
 In consideration of the foregoing, the undersigned hereby agrees that the undersigned will not, and will cause any
spouse or immediate family member of the spouse or the undersigned living in the undersigned’s household not to, without the prior written consent of the Placement Agent (which consent may be withheld in its sole discretion), (i) directly
or indirectly, sell, offer, contract or grant any option to sell (including without limitation any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-1(h) under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise dispose of any Shares, options or warrants to acquire Shares, or securities exchangeable or exercisable for or convertible into Shares currently or hereafter owned
either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned (or such spouse or family member), (ii) enter into any swap, hedge or other agreement or arrangement that transfers, in whole or in part,
the economic risk of ownership of any Shares or securities exchangeable or exercisable for or convertible into Shares, (iii) engage in any short selling of any Shares or securities exchangeable or exercisable for or convertible into Shares, or
(iv) or publicly announce an intention to do any of the foregoing, for a period commencing on the date hereof and continuing through the close of trading on the date 180 days after the date of the closing of the Offering (the
“Lock-up Period”); provided, that the foregoing restrictions shall not apply (a) to the transfer of any or all of the Shares owned by the undersigned, either during the undersigned’s lifetime or on death, by gift,
will or intestate succession to the immediate family of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned and/or a member or members of the undersigned’s immediate family; provided, however, that in
any such case, it shall be a condition to such transfer that the transferee executes and delivers to the Company an agreement stating that the transferee is receiving and holding the Shares subject to the provisions of this letter agreement, and
there shall be no further transfer of such Shares, except in accordance with this letter agreement or (b) the exercise of stock options or warrants, provided further, that the Shares received upon such exercise shall be subject to the
terms of this agreement. For the purposes of this paragraph, “immediate family” shall mean the spouse, domestic partner, lineal descendant (including adopted children), father, mother, brother or sister of the transferor. 

  
 22.









 The foregoing restrictions shall not apply to the transfer of any or all the Shares owned by
the undersigned in connection with any merger or plan of reorganization that is approved by the Board of Directors of the Company. The undersigned expressly agrees that the foregoing restrictions shall in the event of any merger or plan of
reorganization that is approved by the Board of Directors of the Company subsequently apply to any securities received by the undersigned in any such merger or plan of reorganization in exchange for Shares or other securities convertible into or
exchangeable or exercisable for Shares. 
 The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company’s transfer agent and registrar against the transfer of Shares or securities convertible into or exchangeable or exercisable for Shares held by the undersigned except in compliance with the foregoing restrictions. 

In addition, during the Lock-Up Period, the undersigned hereby waives any and all notice requirements and rights with respect to
registration of securities pursuant to any agreement, understanding or otherwise setting forth the terms of any security of the Company held by the undersigned, including any registration rights agreement to which the undersigned and the Company may
be party. 
 This agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal
representatives, and assigns of the undersigned. However, it is understood that, if (i) the Company notifies the Placement Agent in writing that it does not intend to proceed with the Offering, or (ii) if the purchase agreements relating
to the Offering (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of the Shares to be sold thereunder, this letter agreement shall immediately be
terminated and the undersigned shall automatically be released from all of the obligations under this letter agreement. 
  

	
	Very truly yours,
	
	  

	(Name of Stockholder – Please Print)
	
	  

	(Signature)
	
	  

	(Name of Signatory if Stockholder is an entity—Please Print)
	
	  

	(Title of Signatory if Stockholder is an entity—Please Print)



  
 23.